Management of Pancreatic Cystic Lesions Using Artificial Intelligence Based on EUS and Multimodal Data
Recruiting
Observational Study
Pancreatic Cystic Lesion
Mucinous Cystadenoma of Pancreas
Intraductal Papillary Mucinous Neoplasm of Pancreas
Pseudocyst Pancreas
Serous Cystadenoma
Neuroendocrine Tumors, NET
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 500 (estimated)
- Sponsor
- Huazhong University of Science and Technology · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The primary objective is to construct a multimodal AI model (Cyst-AI) based on EUS images and clinical data such as imaging features(CT or MRI) and laboratory tests to assist endoscopists in the diagnosis of pancreatic cystic lesions(PCLs), mainly differentiating mucinous from non-mucinous lesions.
The secondary objective is to evaluate the model's effectiveness in risk stratification and clinica…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion criteria:
* Patients whose EUS results indicates pancreatic cystic or cystoid lesions;
* Mucinous lesions: including mucinous cystic neoplasm (MCN), intraductal papillary mucinous neoplasm (IPMN);
* Non-mucinous lesions: including pancreatic pseudocyst, serous cystic neoplasm (SCN), cysti…
Contacts